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Autosomal-dominant medullary cystic kidney diseaseFurther evidence for linkage of autosomal-dominant medullary
(ADMCKD; MIM 174000) is a rare chronic tubulointer-cystic kidney disease on chromosome 1q21.
Background. Autosomal-dominant medullary cystic kidney stitial nephropathy that has many clinical and morpho-
disease (ADMCKD) is characterized by the development of logical features similar to juvenile nephronophthisis
cysts at the corticomedullary border of the kidneys. It resembles (NPH; MIM 256100). The most striking differences be-nephronophthisis (NPH) with an autosomal-recessive mode of
tween these entities are the age of onset of the diseaseinheritance. Genetic linkage has been shown either on chromo-
and the mode of inheritance, which is recessive in NPH.some 1q21 (ADMCKD1) or 16p12 (ADMCKD2), and families
exist who are not linked to the aforementioned loci. No disease- Autosomal-dominant medullary cystic kidney disease
causing gene underlying this disorder has been reported. is usually diagnosed in the fourth decade of life [1]. How-
Methods. The Finnish Transplantation Register and hospital ever, there are reports in which the patients have beenrecords were searched to identify all of the ADMCKD families
children, and ages at the end-stage renal disease (ESRD)in the Finnish population. Detailed clinical information of the
vary between 5.5 and 64 years [2–6]. In other reports ofpatients was collected. Linkage analysis was used to study
whether the Finnish families originating from a homogenous ADMCKD, patients have been adults, between 19 years
population showed genetic linkage to the ADMCKD1 or and 78 years at end-stage renal failure [7–17]. Hyperten-
ADMCKD2 loci. Also, the coding region of a strong candidate sion is the most common first symptom of the disease.gene, natriuretic peptide receptor A (NPRA), located on the
The patients’ urinary concentration ability is defective.chromosome 1q21 critical region, was sequenced using poly-
Urine analysis produces normal results. Renal failure ismerase chain reaction sequencing with an ABI 377XL Auto-
mated DNA sequencer (Applera Corp., Norwalk, CT, USA). progressive, and the condition has to be treated with dial-
Results. Five of the six families showed linkage to the pre- ysis and renal transplantation. Cysts of variable size de-
viously identified region of chromosome 1q21. Family 6 with velop in the medullary or corticomedullary regions ofhyperuricemia as a prominent clinical feature was linked to
the kidneys, but they do not appear in all patients andneither of the ADMCKD loci. Wide interfamiliar and intrafam-
are not necessary for the diagnosis. Thickening of theiliar variability in the clinical picture of the patients was de-
tected. The NPRA gene mutation was excluded as a causative tubular basement membrane is the most characteristic
gene by sequencing. sign seen in ADMCKD as well as in juvenile NPH [18, 19].
Conclusion. This study locates the gene for ADMCKD1 In recessively inherited NPH end-stage renal failureclose to a marker D1S1595 in a region 5 cM, and further
is reached around 10 years of age. The most common firstconfirms the existence of at least three loci for the medullary
signs of the disease are anemia, growth retardation, poly-cystic kidney disease. Heterogeneity of the symptoms compli-
cates the clinical diagnosis and classification of the patients. dipsia, and polyuria. The recessive and dominant forms
Further studies are needed to identify the disease-causing gene. cannot be differentiated from each other by renal biopsy
or by examining the occurrence of renal cysts. The clearest
difference between them is the mode of inheritance [1].
Molecular genetic studies have already facilitated the
beginning of classification of heterogeneous NPH and
ADMCKD. The NPH locus was assigned by linkageKey words: linkage analysis, chromosome 1, polycystic kidney disease,
analysis to chromosome 2q13 [20–22]. The gene for NPHcysts, Finnish population study, natriuretic peptide receptor A, inher-
ited disease. type 1, NPHP1, has been identified [23, 24], and allelism
between NPH1 locus and ADMCKD has been excludedReceived for publication October 17, 2000
[17]. Two loci for ADMCKD have recently been estab-and in revised form April 31, 2001
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[25] and the second on chromosome 16p12 (ADMCKD2) study; those with occasional low-grade proteinuria, that
is, below 0.3 g/L, were included. Special attention wasto a critical region of 10.5 cM for one Italian family [6].
paid to the occurrence of hyperuricemia and/or gout,In addition to progressive renal failure and hypertension,
which were reported by Scolari et al and Stavrou et alhyperuricemia and gout were represented in both of
[6, 17]. Serum urate levels were examined and/or patientsthese families. The existence of at least a third locus
were asked whether they had experienced gout episodeswas confirmed by Kroiss et al in five families without
in the past. Blood pressure was measured and/or ana-hyperuricemia and gout [26]. Quite recently, Cohn et al
lyzed through all available hospital records, especiallyreported the localization of the disease-causing gene to
at the beginning and during the progression of renal fail-chromosome 1q21 in an Iraqi Jewish family whose mem-
ure. The minimum criteria for considering somebodybers have nephropathy and hypertension [9]. Familial
affected were progressive renal failure based on elevatedjuvenile gouty nephropathy (FJGN; MIM 162000) is an
serum creatinine value and/or early-onset hypertensionautosomal-dominant disease characterized by juvenile
under the age of 30 years. Four of these families haveonset of hyperuricemia, gout, and progressive renal fail-
been partially reported previously [1].ure. In two out of three Czech families, a locus for FJGN
Genealogical studies were performed, and the familieswas assigned to chromosome 16p11.2 [27]. However,
were traced back four to six generations in a search fornone of the genes or their mutations that cause the pre-
common ancestors.viously mentioned disorders have been identified. One
Each family members’ informed consent was obtainedof the strong candidate genes in the 1q21 region is the
before collecting their blood samples.NPRA gene encoding atrial natriuretic peptide (ANP)
receptor A (MIM#108960). Linkage analysis
The purpose of this study was to examine the preva-
DNA was extracted from the blood samples (10 mL)lence of ADMCKD in the isolated Finnish population
according to a standard procedure modified to accommo-and to investigate whether the two previously identified
date Phase Lock Gel tubes (5→ 3). Eleven microsatel-gene loci on chromosomes 1q12 and 16p12 are responsi-
lite markers were selected to cover the critical region ofble for ADMCKD in Finnish families. We found a total
chromosome 1q21 and five markers to cover the chromo-of six affected families, five of them with a genetic linkage
some 16p12 region. Microsatellite polymorphic markersto chromosome 1. One family with ADMCKD and gout
were obtained from the Genome Database (http://www.could not be assigned to chromosomes 1 nor 16. Further-
gdb.org; Table 2). We also analyzed a polymorphic re-more, we excluded the NPRA gene as a candidate gene
peat residing in the promoter region of the NPRA gene
for ADMCKD based on its involvement in the regulation [31]. An MJ Research programmable thermal cycler (MJ
of blood pressure and extracellular fluid volume [28–30]. Research, Watertown, MA, USA) was used to perform
the polymerase chain reactions (PCRs). The fluorescent-
labeled fragments were separated on an ABI 377XL auto-METHODS
mated DNA sequencer (Applera Corp., Norwalk, CT,Patients
USA) with Genescan version 2.1 software (Applera Corp).
A nationwide search was made to find all possible pa- Two-point linkage analyses were performed by the
tients with ADMCKD in Finland. Two approaches were MLINK program of the LINKAGE package [32, 33].
used to reach as complete an ascertainment as possible. The disease gene frequency was set to 104. Marker allele
First, all renal transplantations in Finland are performed frequencies were calculated from analysis of the patient
at Helsinki University Central Hospital starting in 1964. material.
The Finnish Kidney Transplantation Register (FKTR)
was started at the same time, and their files and hospital Physical mapping
records were evaluated. Second, a letter with a descrip- To localize the NPRA gene in respect to the markers
tion of NPH-ADMCKD and a request to report espe- studied, the DNA of 11 YACs (643_h_5, 709_c_5, 734_d_9,
cially early cases that could not be identified as FKTR 736_f_4, 742_f_6, 764_a_1, 776_e_9, 776_h_9, 890_e_4,
was sent to nephrologists of five university and 16 central 950_e_2, and 995_e_1) localized to the 1q21 region was
hospitals. amplified by PCR. In addition, the genetic map of Marsh-
An autosomal-dominant inheritance pattern had to be field Genetic Research Foundation (http://research.
seen in the families included in the study. A renal biopsy marshfieldclinic.org/genetics/Default.htm) was used. The
specimen from at least one affected individual of each YACs were obtained from the CEPH YAC Library (Paris,
family had to be available that showed the characteristic France).
changes of tubulointerstitial nephritis, especially thick-
Sequencing of the NPRA geneening of the tubular basement membrane. The specific
gravity of the patients’ urine had to be lowered. Patients The PCR amplification of the 22 exons forming the
coding region of the NPRA gene was performed in twowith hematuria or proteinuria were excluded from the
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affected individuals 3 and 23 and one healthy control Family 3. In this family, the ages of first symptoms and
especially the ages at ESRD or death vary substantially,(individual 2) [34]. The PCR products were purified by
treatment with 0.5 U shrimp alkaline phosphatase and from 34 to 55 years. Patient 4 reached end-stage renal
failure at the age of 55 years. However, her brother2.5 U exonuclease at 37C for 25 minutes, followed by
inactivation for 15 minutes at 80C. The purified products (patient 5) has been an obligatory carrier and died of
an unspecified lung disease at the age of 64 years withoutwere sequenced directly using the ABI-PRISM dye ter-
minator cycle sequencing ready reaction kit (Applera any symptoms or signs referring to ADMCKD. Family
member 14 died accidentally at the age of 47 years. ItCorp.) on an ABI 377 automatic sequencer. Sequencing
results were compared with the reference human NPRA is reasonable to assume that he died before developing
any symptoms of the kidney disease.sequence (GenBank accession numbers AF190631) by
use of Sequencer 4.05 (GeneCodes). Both strands were Family 4. Family 4 is a small pedigree. Patient 17 had
characteristic signs and symptoms of ADMCKD. She issequenced.
54 years at the moment, and her healthy brother is 52
years.RESULTS
Family 5. In this family, hypertension has been the
Patients first symptom of ADMCKD. With patients 22 and 3, the
Altogether six families with ADMCKD were found progression of the disease has been 9 to 10 years from
consisting of 33 individuals, of which 19 were affected the first symptoms to ESRD. A sister of patient 3 had
(Figs. 1 and 2). The clinical and laboratory findings of died of uremia at about the age of 40 years. Patients 23
the patients of the six families are shown in Table 1. The and 24 are still in the progressive phase. No episode of
ages at ESRD varied from 25 years to 55 years. gout has occurred in this family.
According to the genealogical studies, no parental con- Family 6. The clinical features of family 6 differ quite
sanguinity was found between any of the families. Fami- a bit from the other families. Patient 29 has had many
lies 3 to 5 originated from the southeastern coast of Fin- difficult epidodes of gout before renal failure, and the
land. This area belongs to the early settlement area of progression of the disease is slow. The intrafamilial vari-
Finland, which was inhabited mainly about 2000 years ago ability of all the symptoms is great in this family. Patient
[35, 36]. The grandparents of families 1 and 2 originate 27 also has had difficult gout, and he is the only who has
from the middle-eastern part of Finland, the so-called received a kidney transplant. Patients 25 and 26 do not
late settlement area inhabited during the 16th century. yet have signs of renal failure. They only have episodes
Family 1. In this family, all of the patients were 30 of gout and hypertension, respectively.
years when the first symptoms of the disease appeared.
Linkage analysisIntrafamilial variation of the age of ESRD or death was
not remarkable and occurred between the ages of 25 Five of the six families (families 1 through 5) with
and 33 years. The progression of the disease from the MCKD showed a linkage to chromosome 1q21 region
first symptoms to ESRD was rapid, a maximum of eight (Fig. 1). Linkage to both chromosome 1q21 and 16p12
years. Anemia was the first observed symptom of the was excluded in family 6 (Fig. 2). On chromosome 1
disease with three patients (6, 7, and 8). None of the critical region, the best two-point LOD scores of 5.43 and
patients had episodes of gout, and the serum urate values 2.31 were obtained for markers D1S1595 and D1S305 at
of the three investigated patients were within the normal   0 (Table 2). Because of the low heterozygosity ratio
limits. Hypertension was not seen within this family. of markers NPRA and D1S2715 (0.48 and 0.57, respec-
Family members 5 and 9 were not systematically studied, tively), the corresponding LOD scores of 0.85 and 1.09
but none of them had experienced anemia, elevated are lower than average in region of interest. Haplotype
blood pressure, or any symptoms that might refer to analysis was performed in order to identify recombina-
ADMCKD. They were 37 and 36 years of age, and all tion events.
the patients of this family had reached ESRD or died In family 3, the affected siblings (31 and 30) shared
under the age of 33 years. the same haplotype (Fig. 1). Identical disease haplotype
Family 2. In family 2, patients 10, 13, and 33 had 6-8-10-14-4-10-4-10-14-4-8 also was observed in family
hypertension as their first symptom of the disease. Two 5, which led us to consider this haplotype to be an ances-
patients have received kidney transplants, and the pro- tral one. The affected cousin (patient 16) shared the dis-
gression from the first elevated serum creatinine values ease haplotype between markers D1S1153 and D1S1679.
Interestingly, part of the disease haplotype was observedto transplantation has been long, from nine to eleven
years. Family member 11 is 60 years of age and has also in a healthy member (patient 40) at D1S2125, al-
though due to the missing parental data and the uninfor-suffered from hypertension for over 30 years, but her
serum creatinine value is still within normal limits. She mativeness of the markers, the extent of sharing cannot
be determined. In families 3, 4, and 5, a common haplotypelives abroad, and it has not been possible for her to
participate in any detailed tests. was observed between markers D1S2624 and D1S1595.
Auranen et al: ADMCKD linked to chromosome 1q211228
Fig. 1. Families 1 through 5 show genetic linkage to chromosome 1.
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Fig. 1 (Continued).
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Fig. 2. Haplotype analysis of family 6 on (A) chromosome 1q21 and (B) chromosome 16p12.
Physical mapping and sequencing tween loci D1S1153 and D1S2624, to a region 5 cM.
The highest two-point LOD score of 5.43 was detectedThe chromosome 1 markers were ordered on the basis
with marker D1S1595 at a theta value of zero. Interest-of our YAC analyses and the available genetic map infor-
ingly, this D1S1595 also gave the highest LOD score inmation. Based on the PCR analysis of the 11 YAC clones
the Cypriot families [25], suggesting that the gene forlocated in the region, markers NPRA, D1S2715, D1S305,
ADMCKD1 might lie very close to this marker. Theand D1S2125 were located within the same clone, 950_e_2.
localization of one candidate gene, NPRA, was estab-However, their mutual order could not be identified.
lished by YAC analyses in the critical region (Fig. 2).Markers D1S2721, D1S1153, D1S2624, and D1S1595
This receptor, located mainly in the kidney, vascularwere not localized in any of the 11 YACs studied from
tissue and adrenal gland, is involved in the signalingthe region (data not shown). The coding region of the
processing mediated by ANP. Mice with targeted disrup-NPRA gene consisting of 22 exons was sequenced and
tion of NPRA showed hypertension, cardiac hypertrophy,excluded as a disease-causing gene for ADMCKD1.
and sudden death [37]. We excluded a disease-causing
mutation in ADMCKD1 in the coding region of this
DISCUSSION functionally relevant candidate gene by sequencing the
22 coding exons.Genetic linkage of ADMCKD was first established to
chromosome 1q21 [25] between marker loci D1S498 and Families 3 through 5 originate from the early settle-
ment area of Finland and have partially the same haplo-D1S2125. We have identified a total of six families with
ADMCKD in Finland, five of them showing linkage to type, suggesting that they might have the same mutation
due to a founder affect. Families 1 and 2, originating fromchromosome 1. Genetic heterogeneity was evident, as
one of our families (family 6) was not linked to either the late settlement area of Finland, possess a different
haplotype and might consequently carry a different mu-the ADMCKD1 or ADMCKD2 gene loci (Fig. 2). Based
on our findings, the disease locus for ADMCKD1 was tation(s). When the clinical phenotype of the patients
carrying the same haplotypes were compared, no clearfurther restricted because of a recombination event be-
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Table 1. Clinical and laboratory findings for patients with autosomal-dominant medullary cystic kidney disease (ADMCKD)
belonging to six families
Serum uric
Family Age Urine- acid/serum
and at first First Blood Serum specific Mild creatinine Renal Age at
patients Sex symptoms symptom pressure creatinine gravity proteinuria lmol/L biopsy Gout ESRD/death
Family 1
12 F ND ND ND ND ND ND ND ND ND 29
14 M ND ND ND ND ND ND ND ND ND 33
3 F 22 Prot HT 238 ND Yes 329/130  No 31.5
4 F 30.5 Uremia HT 	800 1.005 No 341/91  No 30.5
8 F 20 Anemia N 100 1.011 No 330/100  No 27.5
6 F 28 Anemia N 152 ND No 344/203 ND No 30
7 M 23.8 Anemia N 223 ND No ND ND No 25.2
Family 2
2 M ND ND ND ND ND ND ND ND ND 51
33 M 42 HT HT 134 1.007 No ND  No 51
13 M 40 HT HT 152 1.005 No 658/537  Yes 48.8
10 M 50 HT HT 123 ND No ND ND No Not yet
Family 3
4 F ND Uremia ND ND ND No ND  No 55
31 M 34.5 Uremia, anemia N 1500 ND No ND ND No 34.5
30 F 40.5 Control: cysts N 100 1.010 No ND ND No Not yet
16 M 38.7 Prot N 163 ND Yes 336/1000  Yes 51.7
429/1041
Family 4
2 F ND ND ND ND ND ND ND ND ND 34
17 F 35 HT HT 174 1.012 No 479/174  No 35
Family 5
3 F 41 ND ND ND ND ND ND ND ND 51
22 F 44 HT HT 230 ND No 403/191  No 52.8
24 F 24.5 HT HT 118 ND No ND  No Not yet
23 M 40 HT HT 137 1.010 No 401/137  No Not yet
Family 6
25 F 60 HT HT 79 ND No ND ND Yes Not yet
26 M 45 HT HT 77 ND No ND ND No Not yet
29 F 5 Short stature N 85 ND No 120/510  Yes Not yet
144/663
27 M 18 Gout N 235 ND No 235/744  Yes 28
The results of the measurements of blood pressure, serum creatinine, urine-specific gravity and proteinuria at the time when the diagnostic evaluations started.
Abbreviations are: ND, not determined; N, normal result; HT, hypertension (	150/90); prot, protein in the urine; , renal biopsy done, typical findings of ADMCKD;
, renal biopsy not done; not yet, end-stage renal disease (ESRD) not yet reached.
Table 2. Two-point LOD scores of the chromosome 1 region with hyperuricemia and gout has been reported [6, 25].
for Families 1 to 5 These extrarenal symptoms were not prominent in our
Two-point LOD scores at  values patients, showing that the absence of these symptoms
does not exclude genetic linkage to the ADMCKD1 lo-Marker 0.0 0.05 0.1 0.15 0.2 0.3 0.4
cus. However, Kroiss et al and Fuchshuber et al excludedD1S534 -infini 2.26 2.26 2.11 1.87 1.24 0.56
genetic linkage to the ADMCKD1 and ADMCKD2 lociD1S498 3.15 2.82 2.48 2.14 1.78 1.08 0.43
D1S2721 -infini 3.00 2.81 2.48 2.10 1.29 0.54 in five families fulfilling the diagnostic criteria without
D1S1153 -infini 3.19 2.97 2.61 2.20 1.33 0.54 gout [26, 38]. In two of the three Czech families withD1S2624 2.17 1.92 1.67 1.42 1.17 0.66 0.22
familial juvenile hyperuricemic nephropathy (FJHN),D1S1595 5.43 4.89 4.33 3.74 3.14 1.89 0.72
NPRA 0.85 0.74 0.63 0.52 0.42 0.22 0.06 linkage to an approximately 10 cM region overlapping
D1S2715 1.09 1.03 0.95 0.85 0.73 0.43 0.14 the critical region of ADMCKD2 on chromosome
D1S305 2.31 2.12 1.91 1.67 1.41 0.86 0.34
16p11.2 has been detected [27]. The affected patientsD1S2125 2.16 2.05 1.85 1.60 1.33 0.75 0.26
D1S1679 -infini 0.13 0.55 0.66 0.63 0.40 0.14 presented the clinical feature of the disease, including
gouty arthritis or renal failure, biochemical evidence ofThe best result of each marker is shown in bold text.
hyperuricemia, reduced fractional excretion of uric acid,
and elevated serum creatinine kinase levels. Genetic het-
erogeneity was evident as a linkage to chromosome 16
correlation could be observed. Instead, prominent differ- was excluded in one family. Also, in the Finnish family
ences were identified especially in the age of the disease material the affected members in family 6 all had early
onset and progression to end-stage renal failure. onset gout, but linkage to ADMCKD1 and ADMCKD2
was excluded.In both ADMCKD1 and ADMCKD2, an association
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16. Wrigley KA, Sherman RL, Ennis FA, Becker EL: ProgressiveRecently, a new locus on chromosome 1q21 was sug-
hereditary nephropathy: A variant of medullary cystic disease?gested for an Iraqi Jewish family with an autosomal- Arch Intern Med 131:240–244, 1973
dominant form of inheritance including progressive renal 17. Stavrou C, Pierides A, Zouvani I, et al: Medullary cystic kidney
disease with hyperuricemia and gout in a large Cypriot family: Nofailure and hypertension [9]. The critical region was
allelism with nephronophthisis type 1. Am J Med Genet 77:149–154,mapped to an interval of approximately 11.6 cM between
1998
markers D1S2696 and D1S2635, overlapping the region 18. Kleinknecht C, Habib R: Nephronophthisis, in Textbook of Clini-
cal Nephrology, edited by Cameron JC, Davison AM, Grunfeldfor ADMCKD1. The patients had increased blood creati-
JP, et al, Oxford, Oxford University Press, 1992, pp 2188–2197nine levels. Renal biopsies also were done on two affected
19. Waldherr R, Lennert T, Weber HP, et al: The nephronophthisisindividuals with no abnormalities. Their urine components complex: A clinicopathologic study in children. Virchows Arch
were also normal. Considering the clinical heterogeneity 394:235–254, 1982
20. Antignac C, Arduy CH, Beckmann JS, et al: A gene for familialbetween and within the families with ADMCKD, the
juvenile nephronophthisis (recessive medullary cystic kidney dis-two diseases may result from different mutations in the
ease) maps to chromosome 2p. Nat Genet 3:342–345, 1993
same gene. 21. Hildebrandt F, Singh-Sawhney I, Schnieders B, et al: Mapping
of a gene for familial juvenile nephronophthisis: Refining the mapIn conclusion, six families were identified in the Finn-
and defining flanking markers on chromosome 2: APN Studyish population with ADMCKD. The majority of them
Group. Am J Hum Genet 53:1256–1261, 1993
are linked to chromosome 1q21. The absence of linkage 22. Medhioub M, Cherif D, Benessy F, et al: Refined mapping of
in one Finnish family with early gout suggests that a a gene (NPH1) causing familial juvenile nephronophthisis and
evidence for genetic heterogeneity. Genomics 22:296–301, 1994third locus exists for ADMCKD in the genome.
23. Hildebrandt F, Otto E, Rensing C, et al: A novel gene encoding
an SH3 domain protein is mutated in nephronophthisis type 1. NatReprint requests to Mari Auranen, M.D., Department of Molecular
Genet 17:149–153, 1997Medicine, National Public Health Institute, Biomedicum, Haartmanin-
24. Saunier S, Calado J, Heilig R, et al: A novel gene that encodeskatu 8, FIN-00290 Helsinki, Finland.
a protein with a putative src homology 3 domain is a candidateE-mail: mari.auranen@ktl.fi
gene for familial juvenile nephronophthisis. Hum Mol Genet
6:2317–2323, 1997
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